| 1. |
- Simrén, Magnus, 1966, et al.
(författare)
-
Update on Rome IV Criteria for Colorectal Disorders: Implications for Clinical Practice
- 2017
-
Ingår i: Current Gastroenterology Reports. - : Springer Science and Business Media LLC. - 1522-8037 .- 1534-312X. ; 19:4
-
Tidskriftsartikel (refereegranskat)abstract
- Purpose of Review: The purpose of the review was to provide an update of the Rome IV criteria for colorectal disorders with implications for clinical practice. Recent Findings: The Rome diagnostic criteria are expert consensus criteria for diagnosing functional gastrointestinal disorders (FGIDs). The current version, Rome IV, was released in May of 2016 after Rome III had been in effect for a decade. It is the collective product of committees that included more than 100 leading functional GI experts. For functional bowel and anorectal disorders, the majority of changes relative to Rome III are relatively minor and will have little impact on clinical practice. However, notable changes with potential impact on clinical practice and research include the changes in the diagnostic criteria for IBS, the modified approach for subtyping of IBS, the view on functional bowel disorders as a spectrum of disorders, and the new definition of fecal incontinence. Summary: New features in the Rome IV diagnostic criteria for functional bowel and anorectal disorders will likely have modest influence on clinical practice, with a few exceptions. © 2017, The Author(s).
|
|
| 2. |
- Törnblom, Hans, 1966, et al.
(författare)
-
Psychotropics, Antidepressants, and Visceral Analgesics in Functional Gastrointestinal Disorders
- 2018
-
Ingår i: Current Gastroenterology Reports. - : Springer Science and Business Media LLC. - 1522-8037 .- 1534-312X. ; 20:12
-
Tidskriftsartikel (refereegranskat)abstract
- Purpose of Review: The functional gastrointestinal disorders, or disorders of gut-brain interaction as defined by the Rome IV criteria, are the most common diagnostic entities in gastroenterology. Treatments that address the dysregulation of gut-brain interaction with these disorders are increasingly gaining interest as a better option than for example traditional analgesics, particularly opioids. Antidepressants, antianxiety and antipsychotic medications, and visceral analgesics, now termed neuromodulators, are included in this update addressing the evidence of treatment benefit in disorders of brain-gut interaction. Recent Findings: By a careful selection based on a multidimensional clinical profile, a decreased symptom burden, particularly regarding abdominal pain, nausea, and vomiting, as well as improved social function and quality of life, can be obtained by use of neuromodulators. There is good evidence for the peripheral neuromodulators from studies in bowel disorders, and the central neuromodulators both from indirect evidence in chronic pain disorders as well as selected disorders of brain-gut interaction. Summary: Basic knowledge about the pharmacologic properties and clinical use of neuromodulators in disorders of brain-gut interaction improves the treatment outcome and avoids use of traditional analgesics. © 2018, The Author(s).
|
|
